News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Pembrolizumab vs Chemotherapy in microsatellite instability – high or mismatch repair – deficient metastatic colorectal cancer
Dec 7, 2024, 10:43

Pembrolizumab vs Chemotherapy in microsatellite instability – high or mismatch repair – deficient metastatic colorectal cancer

Yakup Ergün, Medical Oncologist at Bower Hospital, shared a recent article by T. André on X:

“Pembrolizumab Vs chemotherapy in microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer: 5-year follow-up from KEYNOTE-177 trial.

  • mFU: 73.3 months.
  • Crossover 62%
  • 5y OS55% vs 44%
  • mOS77.5 vs 36.7 months
  • (2y PFS48.3% — CM-8HW72%)
  • Pembrolizumab ? Nivo+İpi?

Title: Pembrolizumab Versus chemotherapy in microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase 3 KEYNOTE-177 study

Authors: T. André, K.-K. Shiu, T.W. Kim, B.V. Jensen, L.H. Jensen, C.J.A. Punt, D. Smith, R. Garcia-Carbonero, J. Alcaide-Garcia, P. Gibbs, C. de la Fouchardiere, F. Rivera, E. Elez,∙ D.T. Le, T. Yoshino, Y. Zuo, D. Fogelman, D. Adelberg and L.A. Diaz

Yakup Ergün

More posts featuring Yakup Ergün.

B.V. Jensen cancer chemotherapy colorectal cancer D. Fogelman K.-K. Shiu L.A. Diaz OncoDaily Oncology pembrolizumab T. André T.W. Kim Yakup Ergün
Special Coverage
Insight
Dec 8, 2024, 06:21
Understanding and treating myelofibrosis
Blog
Dec 8, 2024, 06:18
Michaela Higgins and Gerry Hanna highlighting the unique strengths of Irish clinical trials - Cancer Trials Ireland
Blog
Dec 8, 2024, 06:13
Rasha Aboelhassan: Really impressed with whole data collected and analysed during Global Cancer Movement meeting
Insight
Dec 8, 2024, 06:05
Alessandro Di Federico: Lung adenocarcinomas with Mucinos Histology
Blog
Dec 8, 2024, 05:58
Advancements in Oncology by Oncology Brothers at ASH24
Societies
Dec 8, 2024, 05:32
Last Call for the SIOPE Radiation Oncology and Paediatric Palliative Care Working Groups Survey
Insight
Dec 8, 2024, 05:30
Brittney Abernathy: My first time at ESMO Asia
Insight
Dec 8, 2024, 05:22
Jérôme Salomon: Delighted to announce the launch of the World Health Organization Global NCD Platform Incentive Grant Programme
Insight
Dec 8, 2024, 05:17
Folakemi Odedina: Grant funding opportunity for prostate cancer researchers in Africa by iCCaRE Consortium
Insight
Dec 8, 2024, 05:13
Angela Lamarca: Update form CHECKMATE-9DW trial in HCC - Asian population with Ipilimumab and nivolumab
Insight
Dec 8, 2024, 05:07
Andrea Apolo: Calling GU junior faculty and fellows for the 2025 GU Early Career Thought Leaders conference
Blog
Dec 8, 2024, 04:49
Thrilled to Welcome Kimryn Rathmell to Our All-Staff Retreat - ASCO